{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:44:47Z","timestamp":1786373087926,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"21-22","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.vaccine.2003.12.020","type":"journal-article","created":{"date-parts":[[2004,1,29]],"date-time":"2004-01-29T10:14:44Z","timestamp":1075371284000},"page":"2881-2886","source":"Crossref","is-referenced-by-count":80,"title":["CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques"],"prefix":"10.1016","volume":"22","author":[{"given":"Dennis M.","family":"Klinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Ivins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2003.12.020_BIB1","unstructured":"Friedlander AM, Brachman PS. Anthrax. In: Plotkin SA, Mortimer EA, editors. Vaccines. Philadelphia (PA): WB Saunders; 1998. p. 729\u201339."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB2","unstructured":"Quinn CP, Turnbull PC. Anthrax. In: Ballow M, Sussman M, editors. Topley and Wilson\u2019s microbiology and microbial infections, 98 A.D. London: Collier. p. 799\u2013818."},{"issue":"12","key":"10.1016\/j.vaccine.2003.12.020_BIB3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm1201-1271","article-title":"Bioterrorism: a clear and present danger","volume":"7","author":"Lane","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1128\/IAI.60.2.662-668.1992","article-title":"Immunization against anthrax with Bacilus anthracis protective antigen combined with adjuvants","volume":"60","author":"Ivins","year":"1992","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2003.12.020_BIB5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0882-4010(88)90015-0","article-title":"Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice","volume":"5","author":"Welkos","year":"1988","journal-title":"Microb Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2003.12.020_BIB6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1286-4579(99)80004-5","article-title":"Molecular pathogenesis of Bacillus anthracis infection","volume":"1","author":"Little","year":"1999","journal-title":"Microb. Infect."},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2003.12.020_BIB7","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2003.12.020_BIB8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2003.12.020_BIB9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"issue":"4\/5","key":"10.1016\/j.vaccine.2003.12.020_BIB10","first-page":"413","article-title":"CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans","volume":"19","author":"Davis","year":"2000","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2003.12.020_BIB11","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/S0264-410X(99)00145-0","article-title":"Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys","volume":"17","author":"Jones","year":"1999","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2003.12.020_BIB12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB14","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.93.7.2879","article-title":"CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN\u03b3","volume":"93","author":"Klinman","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7","key":"10.1016\/j.vaccine.2003.12.020_BIB15","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.167.7.3555","article-title":"Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells","volume":"167","author":"Takeshita","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA","volume":"157","author":"Ballas","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/cimm.1996.0009","article-title":"Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha","volume":"167","author":"Halpern","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/oli.1.1998.8.181","article-title":"Therapeutic applications of CpG-containing oligodeoxynucleotides","volume":"8","author":"Klinman","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/eji.1830270931","article-title":"CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants","volume":"27","author":"Lipford","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB21","first-page":"171","article-title":"Use of CpG DNA for enhancing specific immune responses","volume":"247","author":"Davis","year":"2000","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0264-410X(98)80122-9","article-title":"CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus","volume":"16","author":"Moldoveanu","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2003.12.020_BIB23","first-page":"15","article-title":"Enhancing vaccines with immune stimulatory CpG DNA","volume":"3","author":"Krieg","year":"2001","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2003.12.020_BIB24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2567.1999.00811.x","article-title":"DNA activates human immune cells through a CpG sequence-dependent manner","volume":"97","author":"Bauer","year":"1999","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.vaccine.2003.12.020_BIB25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and function of a newly identified CpG DNA motif in human primary B cells","volume":"164","author":"Hartmann","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB26","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs","volume":"166","author":"Verthelyi","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.vaccine.2003.12.020_BIB27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/IAI.58.2.303-308.1990","article-title":"Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen","volume":"58","author":"Ivins","year":"1990","journal-title":"Infect. Immun."},{"issue":"11-12","key":"10.1016\/j.vaccine.2003.12.020_BIB28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2003.12.020_BIB29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00002371-200307000-00003","article-title":"Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides","volume":"26","author":"Leifer","year":"2003","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.vaccine.2003.12.020_BIB30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/(SICI)1096-9071(200003)60:3<324::AID-JMV11>3.0.CO;2-D","article-title":"Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy","volume":"60","author":"Eggers","year":"2000","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.vaccine.2003.12.020_BIB31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF01584360","article-title":"Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women","volume":"17","author":"Cozon","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2003.12.020_BIB32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8","article-title":"Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells","volume":"28","author":"Sparwasser","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm0897-849","article-title":"Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants","volume":"3","author":"Roman","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB34","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1073\/pnas.95.26.15553","article-title":"CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice","volume":"95","author":"Brazolot Millan","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB35","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.4049\/jimmunol.161.9.4463","article-title":"CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice","volume":"161","author":"McCluskie","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0264-410X(98)80122-9","article-title":"CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus","volume":"16","author":"Moldoveanu","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-2143(96)90035-9","article-title":"Amplification of antibody production by phosphorothioate oligodeoxynucleotides","volume":"128","author":"Branda","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.vaccine.2003.12.020_BIB38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.162.3.1611","article-title":"CpG oligonucleotides can cirmcuvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming","volume":"162","author":"Kovarik","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB39","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1084\/jem.188.12.2335","article-title":"Type I interferon-mediated stimulation of T cells by CpG DNA","volume":"188","author":"Sun","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1189\/jlb.71.5.813","article-title":"Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides","volume":"71","author":"Gursel","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.vaccine.2003.12.020_BIB42","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/IAI.67.11.5658-5663.1999","article-title":"Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection","volume":"67","author":"Klinman","year":"1999","journal-title":"Infect. Immun."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04000167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04000167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T20:11:36Z","timestamp":1682626296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04000167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":42,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0264410X04000167"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.12.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}